Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

By M. Chalabi, Lorenzo F. Fanchi, K. Dijkstra, J. G. van den Berg, A. Aalbers, K. Sikorska, M. Lopez-Yurda, C. Grootscholten, G. Beets, P. Snaebjornsson and 18 more. Nature Medicine, 2020

1,218 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/90f718b0e32d0c7faa0ff44ac1f2cf16f975e0f7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Nijman
2. S. Paijens
3. M. de Bruyn
4. A. Vledder

Citations in the corpus

• Tumor-infiltrating lymphocytes in the immunotherapy era (2020, background): “In addition, neoadjuvant administration of ICB produces a superior response in MSI CRC, as demonstrated by the 100% pathological response rate in dMMR tumors and only 27% response rate in mismatch repair-proficient tumors.(211) Taken together, these data demonstrate that mutational burden is highly ”